XLY Auxly Cannabis Group Inc

Today Dosecann, a proprietary in-house brand owned by Auxly Cannabis Group Inc. (TSXV.XLY) (“Auxly”), announces the launch of Dosecann Capsules, a new, high-quality, precision-dosed cannabis product that combines high-potency, broad-spectrum cannabinoids with omega-rich Ahiflower® oil. Ahiflower oil is a sustainable, plant-based source of the complete and balanced essential omegas the body needs.

Dosecann CBD+Ahiflower Oil Capsules are available now at licensed cannabis retailers across Canada, and also available to patients at Medical Cannabis by Shoppers Drug Mart. In coming weeks, Dosecann will introduce 1:4 (THC:CBD) and THC-based formulations, also using Ahiflower oil.

Dosecann Capsules were developed by a team of scientists and researchers at the state-of-the-art laboratory at the Dosecann facility in Charlottetown, PEI, under the direction of Dr. Bob Chapman, Dosecann’s Chief Science Officer.

“Our innovation team has thoroughly researched and rigorously tested Dosecann Capsules to ensure they are consistent with our guiding principles of quality, safety and efficacy,” said Dr. Bob Chapman, Chief Science Officer, Dosecann. “Balanced, omega-rich Ahiflower oil has proven to be an ideal carrier oil for Dosecann’s refined cannabis resins, which feature the full range of cannabinoids, terpenes, flavonoids and other phytonutrients found in the cannabis plant. The resulting capsule formulations offer all the natural qualities of the cannabis and Ahiflower plants in a convenient capsule format that wellness consumers are sure to love.”

“Dosecann Capsules are a milestone launch, a truly differentiated offering for the wellness consumer segment,” said Brad Canario, Brand Director, Auxly. “Research tells us that consumers are looking for innovative cannabis products in familiar formats that fit their wellness needs and regimens, and we’re thrilled to offer a suite of Dosecann Capsules that combine our consistent and potent cannabinoids with a sustainable and omega-rich carrier oil derived from Ahiflower seeds.”

The cannabinoids in Dosecann Capsules are derived from a whole-plant cannabis resin that preserves the character of the cannabis plant. Through a process of cold-ethanol extraction, this broad-spectrum cannabis resin is further refined and combined with omega-rich Ahiflower oil. Ahiflower oil is exclusively available to Auxly for use in cannabis products through a proprietary, multi-year agreement with Natures Crops International, a vertically integrated grower and manufacturer of plant-based specialty oils. By using Ahiflower oil as a carrier, Dosecann Capsules are immediately differentiated from the vast majority of cannabis oil capsules available in the Canadian marketplace, most of which use MCT. In fact, Dosecann Capsules with Ahiflower are the only capsules that provide consumers with broad-spectrum cannabis and the essential omegas the body needs.

The following list highlights the unique characteristics of Ahiflower oil1, which cannot be attributed to MCT oil:

• a source of sustainable, traceable, and balanced omega 3-6-9 oil, with a more biologically advanced omega fatty acid composition than any other natural plant-based oil;
• provides an optimal 4:1 ratio of the essential omega 3-6 fatty acids the body needs;
• has been shown in clinical trials2 to be safe, well-tolerated, and to increase the concentrations of long-chain omega-3 fatty acids up to four times more effectively than flaxseed oil;
• unlike flax seed, Ahiflower also contains omega 6 gamma linolenic acid (“GLA”);
• a sustainably and regeneratively farmed, non-GMO oilseed crop that does not adversely impact ocean ecosystems. Each acre of Ahiflower produces as much omega-rich oil as 320,000 anchovies, frequently used in fish oil.  

Click here for more information about the clinical trials conducted with Ahiflower oil.

According to Healthline, essential polyunsaturated omega 3-6-9 oils are clinically associated with a range of health benefits, such as improving cardiovascular health, supporting mental health, fighting inflammation and benefitting skin and hair.

Dosecann CBD Capsules are available in packages of 30, with each capsule containing 25 mg of CBD, 1 mg of THC and 500 mg of Ahiflower oil. The per-capsule omega fatty acid composition is approximately 320 mg of omega 3 (104 mg of stearidonic acid [SDA] + 216 mg of alpha-linolenic acid [ADA]), 85 mg of omega 6 (28 mg GLA + 57 mg of linoleic acid [LA]) and 51 mg of omega 9 oleic fatty acid. In coming weeks, Dosecann will introduce 1:4 Capsules, with each capsule containing 10 mg of CBD and 2.5 mg of THC; and THC Capsules, with each capsule containing 2.5 mg of THC.

The mixture of cannabinoids and Ahiflower oil is then sealed in Lonza’s Licaps® Capsugel® capsules, which are part of Auxly’s multi-year license with Lonza, a global leader in life sciences. Licaps’ patented technology promotes precise, standardized dosing, a longer shelf-life, and rapid digestion. Airtight and leak-proof, Dosecann Capsules are easy to swallow, odorless and tasteless. Click here for more information on the clinical data about Capsugel capsules.

About Dosecann        Dosecann is a world-class developer of innovative cannabis products for the wellness-focused consumer, wholly owned by Auxly Cannabis Group Inc. Proudly processed at Auxly’s 52,000 sq. ft., state-of-the-art facility in Charlottetown, Prince Edward Island, Dosecann products are developed and manufactured on-site by a world-class team of scientists and experts, ensuring high-quality, precision and consistency. Dosecann’s wellness products, available at licensed cannabis retailers across Canada, consist of non-GMO capsules and oils. Built on the pillars of quality, safety and efficacy, Dosecann is cannabis – down to a science.

Learn more at www.dosecann.com and stay up to date at Twitter: @Dosecann; Instagram: @dosecann; Facebook: @dosecann.

About Auxly Cannabis Group Inc. (TSX.V: XLY) (OTCQX: CBWTF)        Auxly is an international cannabis company dedicated to bringing innovative, effective, and high-quality cannabis products to the medical, wellness and adult-use markets. Auxly's experienced team of industry first-movers and enterprising visionaries have secured a diversified supply of raw cannabis, strong clinical, scientific and operating capabilities and leading research and development infrastructure in order to create trusted products and brands in an expanding global market.

Learn more at www.auxly.com and stay up to date at Twitter: @AuxlyGroup; Instagram: @auxlygroup; Facebook: @auxlygroup; LinkedIn: company/auxlygroup/.

For more information please contact:Scott Campbell, 647-402-4957, press@auxly.com 

Notice Regarding Forward Looking Information:

This news release contains certain "forward-looking information" within the meaning of applicable Canadian securities law. Forward-looking information is frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or information that certain events or conditions "may" or "will" occur. This information is only a prediction. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking information throughout this news release. Forward-looking information includes but is not limited to: Dosecann’s execution of its product development and commercialization strategy; consumer preferences; political change, future legislative and regulatory developments involving cannabis, cannabis products and cannabis health products; and competition and other risks affecting Auxly in particular and the cannabis industry generally.

A number of factors could cause actual results to differ materially from a conclusion, forecast or projection contained in the forward-looking information in this release including, but not limited to whether: there is acceptance and demand for current and future Dosecann products by consumers and provincial purchasers, and general economic, financial market, regulatory and political conditions in which Auxly operates will remain the same. The forward-looking information in this release is based on information currently available and what management believes are reasonable assumptions. Forward-looking information speaks only to such assumptions as of the date of this release. In addition, this release may contain forward-looking information attributed to third party sources, the accuracy of which has not been verified by Auxly. The forward-looking information contained in this release is expressly qualified by the foregoing cautionary statements and is made as of the date of this release. Except as may be required by applicable securities laws, Auxly does not undertake any obligation to publicly update or revise any forward-looking information to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, whether as a result of new information, future events or results, or otherwise.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

1 Source: ahiflower.com. 2 Journal of Nutritional Science. “Consumption of Buglossoides arvensis seed oil is safe and increases tissue long-chain n-3 fatty acid content more than flax seed oil – results of a phase I randomised clinical trial.” Natalie Lefort, Remi LeBlanc, Marie-Andrée Giroux and Marc E. Surette. 2016.

Photos accompanying this announcement are available athttps://www.globenewswire.com/NewsRoom/AttachmentNg/5dfbcf80-7824-4810-b2a5-6b653ab65983

https://www.globenewswire.com/NewsRoom/AttachmentNg/df5c1116-3d85-4b44-a918-c0d82845c849